Budget 2018-19

  The technical advisory group will now meet on November 3 for a final assessment. The World Health Organisation’s technical advisory group on Tuesday sought “additional clarifications” from  Bharat Biotech  for its Covid-19 vaccine Covaxin to conduct a final “risk-benefit assessment” for Emergency Use Listing of the vaccine. The technical advisory group will now meet on November 3 for a final assessment. Hyderabad-based Bharat Biotech, which has developed Covaxin, had submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine’s Emergency Use Listing (EUL). The technical advisory group met on Tuesday to review data on Covaxin for the emergency use listing of India’s indigenously-made vaccine. “The TAG met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine,” the WHO said in an email response to a question by PTI on the decision re...

  Animal vaccine maker Hester Biosciences, on the other hand, is setting up a greenfield BSL-3 facility in Gujarat to make Covaxin Covaxin might soon be produced in the neighbourhood of Covishield after Hyderabad-based vaccine maker  Bharat Biotech  started engineering batches of Covaxin at Biovet’s Manjari plant near Pune. Meanwhile, Covaxin production will touch 55 mn doses a month from October.Biovet is an associate firm of Bharat Biotech. “At present engineering batches are on at the Manjari plant. Soon, commercial production will start,” said a source close to the developments. ngineering batches are run to test the functionality of the installed equipment. The Manjari plant spread over 12 hectares was acquired by Biovet. It is a ready to use vaccine plant that belonged to a Merck & Co subsidiary Intervet India. Intervet is exiting business operations in India and has thus sold the Manjari unit to Biovet. Meanwhile, Krishna Ella, chairman and managing director of...